Investments
Jan. 27, 2004
Drug Company Novacea Secures $35 Million Influx
The money continues to flow into drug company Novacea Inc., and Silicon Valley lawyer Alan Mendelson couldn't be happier. Novacea has secured $35 million in third-round financing, which will advance the company's development of cancer treatments. The company's lead drug is under clinical evaluation for treating prostate cancer and lung cancer.
Novacea has secured $35 million in third-round financing, which will advance the company's development of cancer treatments. The company's lead drug is under clinical evaluation for treating prost...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In